Search Results - "Benavides, LC"

Optimal method of dosing HER2/ neu peptide vaccines: U.S. Military Cancer Institute Clinical Trials Group Study 1-01, 1-02, 1-03, and 1-04 by Benavides, LC, Gates, JD, Holmes, JP, Mittendorf, EA, Ponniah, S, Peoples, GE

“…Abstract Abstract #3139 Background: Our Cancer Vaccine Development Program has performed phase I and II clinical trials using immunogenic peptides from the…”
Get full text

Incidence of hormone-receptor negative and basal type breast tumors among HLA-A2+ patients and possible implications for cancer vaccine trials: U.S. Military Cancer Institute clinical trials group study I-01, I-02, I-03, and I-04 by Holmes, JP, Benavides, LC, Gates, JD, Mittendorf, EA, Ponniah, S, Peoples, GE

“…Abstract Abstract #3153 Background: Breast cancer prognosis is significantly impacted by expression levels of steroid hormone receptors for estrogen (ER) and…”
Get full text

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37) by Gates, JD, Benavides, LC, Carmichael, MG, Hueman, MT, Holmes, JP, Khoo, S, Stojadinovic, A, von Hofe, E, Ponniah, S, Peoples, GE

“…Abstract Abstract #3134 Background: CD4+CD25+FOXP3+ regulatory T cells (Tregs) have been implicated in the suppression of immune responses against various…”
Get full text